Sidem Pharma

Sidem Pharma Sa

Negma-lerads

Laboratoires Negma

Mitsubishi Tanabe Pharma Corporation

Steba Maor Sa

Abenhaim, Lucien

Suzy Charbit

Avraham Cohen

François Schutze

Hervé Ficheux

Michel Homerin

Francois Schutze

Alain Taccoen

Frédéric Martinet

Gérard Coquerel

Jean-Pierre Gesson

Martine Mondon

Guillaume Tauvel

Marie-Noëlle Petit

Patricia Gizecki

Nadia Fonteneau

Jean-Pierre Pelletier

Diego Provvedini

Stéphane Bernad

Bertrand Gaillac

Yoshio Inaba

Lucien Abenhaim

The invention relates to conglomerates of tenatoprazole potassium salts of the following general formula (I), that consist of an equimolar mixture of enantiomers having R and S configurations and capable of crystallization in the form of a conglomerate, wherein said salts are selected from tenatoprazole dehydrated potassium salt, tenatoprazole potassium dimethanolate, tenatoprazole potassium diethanolate and tenatoprazole potassium ethylene-glycolate. The invention also relates to a pharmaceutical composition containing such salt, and to the use of said salt. 

Conglomerates of tenatoprazole potassium salts

The invention relates to enantiomer (&#x2212;) of tentoprazole. The inventive enantiomer (&#x2212;) of tenatoprazole, or (&#x2212;)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazol[4,5-b]pyridine exhibits improved pharmacokinetic properties which make it possible to use a once a day posology of a drug for relevant indications. The enantiomer (&#x2212;) of tentoprazole can be used for treating digestive pathologies.

Enantiomer (-) of tenatoprazole and the therapeutic use thereof

The present invention concerns enantioselective preparation of sulphoxide derivatives or their salts. The method consist in performing an enantioselective oxidation of a sulphur of general formula (I) A &#x2014;CH&#x2014;SB, wherein: A is a diversely substituted pyridinyl ring and B is a heterocyclic radical comprising an imidazo-pyridinyl ring, using an oxidizing agent in the presence of a titanium-based catalyst and a chiral ligand consisting of a cyclic beta or gamma-amino-alcohol, in an organic solvent, followed, if required, by salt formation with a base. The invention is useful for preparing sulphoxides useful in therapeutics.

Method for enantioselective preparation of sulphoxide derivatives

The present invention relates to S-tenatoprazole monohydrated sodium salt, represented by the following formula and the use thereof in therapy for the treatment of digestive diseases.

Monohydrated sodium salt of S-tenatoprazole and the use thereof in therapy

The invention relates to enantiomer (&#x2212;) of tentoprazole. The inventive enantiomer (&#x2212;) of tenatoprazole, or (&#x2212;)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazol[4,5-b]pyridine exhibits improved pharmacokinetic properties which make it possible to use a once a day posology of a drug for relevant indications. Said invention can be used for curing digestive pathologies.

The invention concerns novel flavone and isoflavone derivatives of formulae (Ia) and (Ib) wherein: X represents a group of formula &#x2014;COOR, or &#x2014;PO(OR); R represents a hydrogen atom or an alkaline or alkaline-earth metal, or a lower alkyl group; Rrepresents a hydroxy group, a lower alkoxy group or an acyloxy group; Rand R, identical or different, represent a hydrogen or halogen atom, or a trifluoromethyl group, a trichloromethyl group, a hydroxy group, an alkoxy group or an acyloxy group comprising 1 to 5 carbon atoms, or Rand Rcan combine to form an alkylene dioxy group. The invention is useful for rheumatic diseases.

7-carboxy-flavone derivatives preparation method and therapeutic use

A method of treating osteoarthritis, which is effective not only at targeting the symptoms of the disease, but also in interrupting, preventing, and controlling cartilage destruction, to thereby favorably alter the course of the disease, comprising the administration of an effective amount of rhein or a rhein derivative, preferably diacerein, either alone or in combination with at least one member selected from the group consisting of analgesics, antipyretics, cortico-steroids, anti-inflammatory agents, cyclooxygenase-2 inhibitors, and inflammatory cytokine inhibitors, to a subject in need of such treatment.

Treatment of osteoarthritis

Growing community of inventors

Creteil, France

Suzy Charbit